valu usd unless otherwis note
view tavr sale growth accur reflect
underli demand also support recent tavr survey
howev disconnect report sale growth demand
surfac certain quarter gener creat better entri point
continu recommend ew long-term core med-tech hold
growth investor prefer buy pullback
revenu ep estim consensu ww
revenu y/i estim
revenu increas revenu exclud
fx higher revenu drove ep beat versu estim
ew exit tavr center increas
year ago tavr revenu sequenti
y/i estim consensu tavr survey
publish earlier week forecast low-single-digit procedur growth
newli ad low-volum center faster
procedur growth manag attribut growth tavr center
rise demand treatment hospit acknowledg
superior outcom rel surgic valv least high-risk
intermediate-risk patient
sale growth facilit faster growth region
low tavr penetr tavr sale adjust
germani stock sale cardioband sale
y/i estim strong y/i growth help
lack sale franc consequ govern
quota system japan continu grow rapidli center
ad high/extreme-risk tavr patient current
treat tavr leav signific room growth
procedur extend intermediate-risk patient
ce mark centera sapien ultra around corner
centera approv europ later month ew intend
price valv premium self-expand valv initi
target intervent cardiologist alreadi use self-expand
valv practic ew plan initi us trial centera
manag anticip european approv sapien ultra
 approv sapien ultra expect year-end
rais estim price target increas
manag forecast ww tavr sale toward high
end initi guidanc issu made
similar comment consolid revenu initi guidanc
owe weaker us dollar strong tavr momentum exit
revis revenu estim
new ep estim ew increas ep
guidanc base lower tax rate stronger
price prior trade day market close estimate unless otherwis note
ew best growth stori large-cap
med-tech view believ ew post
revenu compound-annual-growth-rate double-digit ep compound-annual-growth-rate faster
large-cap compani coverag univers
manag project ww tavr market
low double-digit compound-annual-growth-rate believ
conserv expect market cross threshold
year earlier exceed forecast includ
revenu contribut low risk indic start
top half guidanc look realist manag
forecast ww revenu
transcathet heart valv sale
ep rang
manag extend
forecast beyond number on-going clinic trial
technolog advanc lay groundwork
continu double-digit growth first half next
centera sapien ultra receiv ce mark
near futur centera self-expand valv
includ motor deploy system centera
price premium self-expand valv market
design featur improv oper experi
devic perform rel sapien sapien ultra
 launch expect late
bloomberg capit market estim upside/downside/target
dcf model yield base case price target
key assumpt follow revenu growth
compound-annual-growth-rate driven double-digit growth
tavr/mitr franchis mid-single-digit growth
two product categori surgic valv critic
ebit margin
tax rate forecast period cash
flow dcf model discount use wacc
upsid scenario valu assum low-double-digit
revenu growth compound-annual-growth-rate driven
expans moder aortic stenosi asymptomat
along meaning revenu contribut
downsid scenario valu assum moder
tavr revenu growth due slower adopt among
intermedi risk patient delay approv low risk
indic stronger competit lack
progress mitral clinic develop program
dcf model yield base case price target key assumpt follow
revenu growth compound-annual-growth-rate driven double-digit growth tavr/
mitral franchis mid-single-digit growth two product categori surgic
valv critic ebit margin tax rate
forecast period cash flow dcf model discount use
wacc price target basi outperform rate ew share
risk rate price target
risk price target rate includ limit increas competit
market opportun currenc litig reimburs clinic trial risk
edward lifesci global player product technolog design treat
cardiovascular diseas compani focus specif cardiovascular opportun
includ heart valv diseas critic care technolog peripher vascular diseas
